Alternative Name
NRAS Gene Sequencing
Methodology
Molecular
Test Description

Bi-directional sequencing of NRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59, and 61. Testing is approved for specimens from the state of New York.

Clinical Significance

NRAS is highly homologous with KRAS; both are members of the most frequently mutated family of oncogenes. NRAS Mutations are found in a wide variety of solid tumors, in advanced systemic mastocytosis, and in myeloid neoplasias.

Specimen Requirements

Peripheral blood: 5 mL in EDTA tube. Bone marrow: 2 mL in EDTA tube. FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*
81311
Turnaround Time

7 days

Level of Service
Global

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.